<DOC>
	<DOC>NCT01090492</DOC>
	<brief_summary>The investigators propose that once daily administration of PF-00489791, a phosphodiesterase inhibitor, will reduce vasospasm and improve symptoms and signs associated with Primary and Secondary Raynaud's Phenomenon.</brief_summary>
	<brief_title>PF-00489791 For The Treatment Of Raynaud's</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Raynaud Disease</mesh_term>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<criteria>Active Raynaud's Phenomenon Stable disease and medication requirements over the previous two months For Secondary Raynaud's Phenomenon subjects, a diagnosis of scleroderma using the American College of Rheumatology criteria or by the presence of at least 3/5 features of CREST syndrome both sexes Uncontrolled hypertension, diabetes mellitus, angina, or using oral nitrates Smoking within 3 months or smoking cessation using nicotine products Subjects currently taking sildenafil, tadalafil or vardenafil Subjects with ulnar arterial occlusive disease as shown by a modified Allen test Pregnant or breast feeding or considering pregnancy in next 4 months Participation in trial for investigational drug within 30 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Raynaud's phenomenon</keyword>
	<keyword>vasospasm</keyword>
	<keyword>scleroderma</keyword>
	<keyword>systemic sclerosis</keyword>
	<keyword>CREST</keyword>
	<keyword>phosphodiesterase inhibitor</keyword>
</DOC>